Sandoz Group

Sandoz Group EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Sandoz Group (SDZ.SW) as of Oct 16, 2026 is 51.20. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 575.79 — a change of -91.11% (lower).

EV/FCF

51.20

YoY

-91.11%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Sandoz Group is 2025 51.20 . EV/FCF (Enterprise Value to Free Cash Flow) of Sandoz Group was 2024 575.79 . It decreases by -91.11% lower compared to the previous year.

The Sandoz Group EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2020
52.43 USD
Jan 1, 2021
44.14 USD
Jan 1, 2022
49.77 USD
Jan 1, 2023
-142.21 USD
Jan 1, 2024
575.79 USD
Jan 1, 2025
51.20 USD
The Sandoz Group EV/FCF history
YEAREV/FCFYoY
51.20-91.11%
575.79-504.89%
-142.21-385.73%
49.77+12.75%
44.14-15.80%
52.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sandoz Group Stock analysis

What does Sandoz Group do? Sandoz Group AG is a pharmaceutical company headquartered in Rotkreuz, Switzerland. It operates in the healthcare sector, specifically within the pharmaceuticals industry. The company went public on October 4, 2023, with its ticker listed as SDZ.SW and ISIN CH1243598427. Sandoz Group AG focuses on two primary business areas: Generics and Biosimilars. The Generics division develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals, as well as anti-infective finished dosage forms and active pharmaceutical ingredients. The Biosimilars division develops, manufactures, and markets protein-based and other biological products that are similar to already approved biological medicines. The company's product portfolio spans multiple therapeutic areas, including cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory conditions. Sandoz Group AG serves customers globally, providing pharmaceutical solutions across various medical fields. The company is based in Switzerland and operates within the pharmaceuticals industry, with its headquarters located in Rotkreuz. It is active in the healthcare technology industry, though specific details about its technology focus are not provided. The company's operations are centered around the development and distribution of generic and biosimilar medications to meet global healthcare needs. Sandoz Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandoz Group stock

EV/FCF (Enterprise Value to Free Cash Flow) of Sandoz Group is 51.20 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Sandoz Group changed from 575.79 to 51.20, representing a -91.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Sandoz Group since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Sandoz Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sandoz Group

All Key Metrics — Sandoz Group